PainReform's LayerBio Platform Accommodates Multiple Drugs
Ticker: PRFX · Form: 6-K · Filed: Dec 10, 2025 · CIK: 1801834
| Field | Detail |
|---|---|
| Company | Painreform Ltd. (PRFX) |
| Form Type | 6-K |
| Filed Date | Dec 10, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: technology-update, drug-delivery, press-release
TL;DR
PainReform's LayerBio ocular platform can now handle multiple drugs, expanding its potential.
AI Summary
On December 10, 2025, PainReform Ltd. announced that its LayerBio drop-less sustained-release ocular platform has demonstrated the ability to accommodate multiple drug entities. This confirmation is based on a press release issued by the company on the same date.
Why It Matters
This development could expand the therapeutic applications of PainReform's ocular drug delivery technology, potentially leading to new treatment options for various eye conditions.
Risk Assessment
Risk Level: low — The filing is an informational press release announcement and does not contain significant financial or operational changes.
Key Players & Entities
- PainReform Ltd. (company) — Registrant
- LayerBio (company) — PainReform's ocular platform
- December 10, 2025 (date) — Date of press release
FAQ
What is the main announcement in the December 10, 2025 press release?
The press release confirms the ability of PainReform's LayerBio drop-less sustained-release ocular platform to accommodate multiple drug entities.
What is the name of PainReform Ltd.'s ocular platform?
The name of the platform is LayerBio.
What type of filing is this document?
This document is a Form 6-K, a Report of Foreign Private Issuer.
When was the press release filed with the SEC?
The press release was filed on December 10, 2025.
What is PainReform Ltd.'s principal executive office address?
The address is 65 Yigal Alon St., Tel Aviv 6744316, Israel.
Filing Stats: 193 words · 1 min read · ~1 pages · Grade level 10.3 · Accepted 2025-12-10 08:37:50
Filing Documents
- zk2534103.htm (6-K) — 9KB
- exhibit_99-1.htm (EX-99.1) — 11KB
- image0.jpg (GRAPHIC) — 370KB
- 0001178913-25-004041.txt ( ) — 531KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Date: December 10, 2025 PAINREFORM LTD. By: /s/ Ehud Geller Ehud Geller Executive Chairman of the Board and Interim Chief Executive Officer